Associated Papers
Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis.
Yang J et al.
Biochemistry and Biophysics Reports, 2025
Resistance to targeted therapies: delving into FLT3 and IDH.
Desikan SP et al.
Blood Cancer Journal, 2022
The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.
Ferng TT et al.
Molecular Cancer Therapeutics, 2022
Exploring the Resistance Mechanisms of Distal D835V Mutation in FLT3 to Inhibitors.
Wang Z et al.
Oxidative Medicine and Cellular Longevity, 2022
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.
Ge SS et al.
Frontiers in Oncology, 2022
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
Joshi SK et al.
American Journal of Hematology, 2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Mizuta H et al.
Nature Communications, 2021
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Tarver TC et al.
Blood Advances, 2020
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
Apsel Winger B et al.
Cancer Research, 2019
Select a paper to view details